S-1: Polomar Health Services Files S-1, Details Executive Pay, Merger

Polomar Health Services, a development-stage compounding pharmacy, filed an S-1 registration statement detailing executive employment, a significant merger, and ongoing financial challenges.

Summary

• Polomar Health Services, Inc. (formerly Trustfeed Corp.) operates Polomar Specialty Pharmacy, a Florida-licensed retail compounding pharmacy, authorized in 28 U.S. states with a goal to reach a majority by end of 2025.
• The company plans to launch SlimRx™ (weight loss) and PoloMeds™ (diabetes, ED, dermatological) online platforms in Q4 2025 and anticipates applying for a drug export permit in Q4 2025.
• A significant merger with Altanine Inc. is planned, where former Altanine stockholders are expected to own approximately 80% of the combined company, contingent on various conditions including stockholder consent and Nasdaq listing.
• The company reported a net loss of $1,341,333 for fiscal year 2024 and $1,062,418 for the six months ended June 30, 2025, with an accumulated deficit of $3,973,581 as of June 30, 2025.
• As of June 30, 2025, the company had only $4,678 cash on hand and negative working capital of ($943,867), raising substantial doubt about its ability to continue as a going concern.
• Terrence M. Tierney has been appointed President, CEO, and Secretary, with a base salary of $27,750 per month, a target annual bonus of 75% of base salary, a sign-on bonus of 125,000 restricted common shares, and 1,000,000 stock options at $0.20 per share.
• The S-1 filing registers 5,114,497 shares of common stock for resale by existing selling stockholders, from which the company will not receive any proceeds.

Sentiment

Score: 3

Explanation: While the company has strategic plans for growth, new product launches, and a significant merger, its current financial state is highly precarious, marked by increasing losses, minimal cash, negative working capital, and substantial related party debt, leading to a 'going concern' warning. The success of future initiatives and the merger is uncertain and contingent on significant capital raises and regulatory approvals.

Positives

• Expansion of compounding pharmacy services to 28 states, with a goal to reach a majority of U.S. states by end of 2025, and plans for a drug export permit in Q4 2025.
• Anticipated launch of new online telehealth platforms, SlimRx™ (weight loss) and PoloMeds™ (diabetes, ED, dermatology), in Q4 2025.
• Licensing of patent-pending intellectual property for proprietary drug delivery systems (aerosol-based sildenafil, sumatriptan, GLP-1 receptor agonists), which could increase drug bioavailability and decrease time to effectiveness.
• Valuation of the licensed IP rights at a net present value of $9,735,000 through December 31, 2029, assuming patent protection.
• Product Fulfillment and Distribution Agreement with ForHumanity, Inc., guaranteeing $750,000 in payments and potential for exclusivity extensions based on revenue targets ($1,500,000 in Q1 2026, $3,000,000 for Jan-Jun 2026).
• Expected competitive advantage in drug delivery (pre-filled injection pens) and an integrated telemedicine platform compared to competitors like Hims/Hers, Ro, and Eli Lilly Direct.

Negatives

• History of significant net losses: $1,341,333 for fiscal year 2024 and $1,062,418 for the six months ended June 30, 2025.
• Accumulated deficit of $3,973,581 as of June 30, 2025.
• Limited cash on hand: $4,678 as of June 30, 2025.
• Negative working capital of ($943,867) as of June 30, 2025.
• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash flow.
• Significant related party short-term debt and other current liabilities totaling $1,036,921 as of June 30, 2025.
• The company will not receive any proceeds from the current S-1 registration for the resale of 5,114,497 shares by selling stockholders.
• The underlying intellectual property for licensed drug delivery systems has not yet been granted patent protection by the USPTO.
• The licensed IP is non-exclusive and terminable on 180 days' notice by either party.
• Revenues decreased to $10,011 for the six months ended June 30, 2025, from $28,105 for the same period in 2024, primarily due to post-merger transition to an online business model.
• Operating expenses increased significantly to $985,755 for the six months ended June 30, 2025, from $364,179 for the same period in 2024.

Risks

• Uncertainty of profitability due to a history of losses and being a development stage company with a limited operating history.
• Failure to obtain adequate financing on a timely basis and on acceptable terms to continue as a going concern.
• Risks related to operations and uncertainties in the business plan and strategy.
• Legislative or regulatory changes concerning prescription drugs and compounding pharmacies.
• Changes in economic conditions.
• Uncertainty with respect to intellectual property rights, protecting those rights, and claims of infringement of others' intellectual property.
• Intense competition from well-established and well-capitalized competitors.
• Cybersecurity concerns.
• No assurance that the planned merger with Altanine Inc. will be successfully consummated, which could result in additional transaction costs, loss of revenue, or other effects.
• Inability to manage rapid growth effectively, placing strain on management and resources.
• Credit market volatility and illiquidity may affect the ability to raise capital.
• Substantial related party short-term debt and other current liabilities may be difficult to repay.
• Viable markets for products may never develop, may take longer than anticipated, or may not be sustainable.
• Failure to meet development and commercialization milestones.
• Dependence on retaining and attracting highly capable management and operating personnel.
• Limited trading market for common stock, making it difficult to liquidate investments.
• No assurance of common stock listing on a national securities exchange.
• Volatility in market price and trading volume of common stock.
• Potential dilution of interest if additional shares of common stock are issued to raise capital.
• Status as a smaller reporting company may make common stock less attractive to investors.
• Common stock is subject to SEC penny stock rules, which makes transactions cumbersome and may reduce value.
• Anti-takeover provisions in charter and bylaws could prevent or frustrate attempts to change management or acquire the company.
• No intention to pay cash dividends in the foreseeable future.
• Increased costs and demands on management as a public company.
• Failure to establish and maintain effective internal controls, with identified material weaknesses.
• Significant portion of outstanding shares are restricted but may be sold in the future, potentially causing stock price decline.
• Lack of research or unfavorable reports from securities or industry analysts could cause stock price and trading volume to decline.
• Selling stockholders' resale of shares could cause stock price to decline and encourage short sales.
• Largest shareholder (CWR and affiliates) has substantial control (approximately 42% voting control), which might not align with other shareholders' interests.

Future Outlook

The company expects to launch its SlimRx™ telehealth platform in early Q4 2025 and PoloMeds™ in Q4 2025. It anticipates providing prescription medications in a majority of U.S. states by the end of 2025 and applying for a drug export permit in Q4 2025. The wholesale part of the business is expected to experience steady growth over the next twelve to eighteen months. The planned merger with Altanine Inc. is expected to result in former Altanine stockholders owning approximately 80% of the combined company, with plans for a Nasdaq listing and securing a minimum $25 million Equity Credit Line. The company expects to continue incurring net losses for the foreseeable future and plans to raise additional capital to fund operations and business opportunities.

Management Comments

• Polomar is actively seeking approval and authorization in other states and expects to be able to provide prescription medications in a majority of U.S. states by the end of 2025.
• Polomar anticipates applying for a drug export permit in the fourth quarter of 2025.
• We expect to launch the SlimRx™ telehealth platform early in the fourth quarter of 2025.
• The Company also expects to launch PoloMeds™ (polomeds.com) during the fourth quarter of 2025.
• This wholesale part of the business is expected to experience steady growth over the next twelve to eighteen months.
• Based upon ForHumanity's forecasted sales, Polomar expects approximately $342,333 in gross revenue for the fourth quarter of 2025 and approximately $621,126 in the first quarter of 2026.
• Over the next twelve months management plans to raise additional capital and to invest its working capital resources in its existing business and other potential business opportunities.
• We believe our pre-filled injection pen system will provide an easier, better, and more comfortable user experience thereby providing us a potential marketing advantage.
• We expect that our pre-filled injection pens will be a more attractive delivery system for most patients, and we will be competitive on pricing.
• We believe that our integrated platform delivering telemedicine to patients and directly fulfilling prescription may provide an advantage and is likely to provide better margins on the products we sell.

Industry Context

Polomar Health Services operates in the highly competitive compounding pharmacy and telehealth sectors, focusing on weight loss, diabetes, erectile dysfunction, and dermatological medications. The company aims to differentiate itself through proprietary drug delivery systems, such as pre-filled injection pens for GLP-1 agonists (semaglutide) and inhalable sildenafil, which it believes offer a superior user experience compared to competitors like Hims/Hers, Ro, and Eli Lilly Direct. While these larger competitors currently hold significant market share and marketing advantages, Polomar's integrated platform for telemedicine and direct prescription fulfillment is expected to provide better margins. The company is also expanding its state licensing and plans for drug export, indicating a strategy to broaden its market reach.

Comparison to Industry Standards

• Compared to Hims/Hers and Ro, who dispense GLP-1 drugs via traditional drug vials and syringes, Polomar believes its pre-filled injection pen system will offer an easier, better, and more comfortable user experience, providing a potential marketing advantage.
• Against Eli Lilly and Company's Lilly Direct, which offers Zepbound at a significant discount but delivers in single-use vials with syringes, Polomar expects its pre-filled injection pens to be a more attractive delivery system for most patients and plans to be competitive on pricing.
• In comparison to direct competitors like Levity Healthcare, Inc. and ZipHealth, Inc., who also deliver injectable medications in sterile bottles with syringes, Polomar believes its pre-filled injector pen system will be a competitive advantage in user experience.
• Polomar's integrated platform, combining telemedicine with direct prescription fulfillment, is expected to provide better margins compared to competitors like Hims/Hers and Ro, who sub-contract fulfillment to other pharmacies.

Management Changes

Corporate Governance

Related Party Transactions

• Polomar Pharmacy borrowed up to $700,000 from Reprise Management, Inc. (an affiliate of Daniel Gordon) via the Reprise Note. As of June 30, 2025, the outstanding principal was $808,875.30 plus $88,674.44 accrued interest. Reprise exchanged $300,000 of this debt for 60 shares of Series A Convertible Preferred Stock. The remaining balance of $597,549.74 is due by July 31, 2027, at 12% annual interest.
• The company borrowed up to $250,000 from CWR 1, LLC (an affiliate of Daniel Gordon) via the CWR Note. As of June 30, 2025, the outstanding principal was $450,000, including accrued interest. CWR exchanged this note for 90 shares of Series A Convertible Stock, considering the note paid in full as of June 30, 2025.
• On July 21, 2025, the company entered a new Promissory Note and Loan Agreement with CWR (Second CWR Note) for up to $150,000, maturing by October 31, 2025, with an initial 12% APR interest. $113,000 has been drawn as of the filing date.
• On July 28, 2025, the company entered a Promissory Note and Loan Agreement with Profesco Holdings, LLC (managed by Terrence M. Tierney, CEO) for up to $100,000, maturing by October 31, 2025, with an initial 12% APR interest. $128,499.22 has been drawn as of the filing date.
• Daniel Gordon (affiliate) personally loaned the Company $10,000 on January 31, 2025, which was repaid by April 1, 2025.
• Affiliates of CWR and GLDLP funded $380,330.30 plus $12,328.51 accrued interest in company expenses from the Transaction through December 31, 2024, which GLDLP expects to be repaid.
• As part of the Polomar Merger, CWR, the majority owner pre-merger, transferred back and canceled 50,000,000 shares of common stock.
• The company licensed intellectual property from Pinata Holdings, Inc., an affiliate of CWR, with royalties ranging from 10% to 20% of net sales.
• Executive compensation for Terrence M. Tierney (Professional Services Agreement and Executive Employment Agreement) and Director Services Agreements for Gabriel Del Virginia and David Spiegel involve compensation in cash and restricted stock.

Stakeholder Impact

• Shareholders face potential for significant dilution from future capital raises and the Altanine merger (current shareholders expected to own 20% post-merger). There is a high risk of investment loss due to going concern issues and a limited trading market. Selling stockholders' resale could depress share price.
• Employees' ability to attract and retain talent is crucial for the company's success, with plans for stock incentive plans and competitive compensation. However, the going concern risk poses a threat to job security.
• Customers (patients) may benefit from new and improved drug delivery systems (pre-filled pens, inhalable medications) and expanded access to compounded medications across more states through the planned launch of SlimRx and PoloMeds platforms.
• Creditors, particularly related parties, have significant exposure to company debt, with short-term maturities on some notes, raising concerns about repayment capacity given the company's financial losses and limited cash.
• Management and Directors' compensation includes stock awards and options, aligning their interests with company performance. However, they face significant challenges in securing financing and achieving profitability.

Next Steps

• Launch SlimRx™ telehealth platform in early Q4 2025.
• Launch PoloMeds™ platform in Q4 2025.
• Seek approval and authorization to provide prescription medications in a majority of U.S. states by the end of 2025.
• Apply for a drug export permit in Q4 2025.
• Respond to USPTO Office Action Letter for SlimRx™ trademark by October 24, 2025.
• Complete the merger with Altanine Inc., contingent on stockholder consent, Nasdaq listing approval, and securing a $25 million Equity Credit Line.
• Effect a reverse stock split to achieve a $10.00 per share price prior to the Altanine Merger closing.
• Raise additional capital to fund operations and business opportunities.
• Invest working capital resources in existing business and other potential business opportunities.
• Potentially add consultants or employees for corresponding operations.
• The Board intends to consider adopting a formal policy concerning the nomination of directors.

Key Dates

Recommendation

Polomar Health Services is a development-stage company facing severe financial distress, evidenced by increasing net losses, minimal cash reserves, negative working capital, and a 'going concern' warning from its auditors. While strategic initiatives like new platform launches and a planned merger with Altanine Inc. offer potential, their success is highly uncertain and contingent on substantial future capital raises. The company's reliance on related-party debt, unproven business model, and the fact that the current S-1 is for selling stockholders (meaning no direct capital infusion to the company) further exacerbate the risk. For a seasoned investor, the current risk profile, coupled with the high likelihood of dilution and potential for further stock price decline, makes the stock a 'sell' until there is clear evidence of sustainable revenue generation, improved financial health, and successful execution of its strategic plans.

Keywords

Compounding Pharmacy, Telehealth, Weight Loss Medications, Semaglutide, Sildenafil, Diabetes Medications, Dermatological Formulations, Drug Delivery Systems, SEC Filing, S-1 Registration, Polomar Health Services, Altanine Merger, Executive Compensation, Related Party Debt, Going Concern, Intellectual Property Licensing